|
Delayed
Japan Exchange
02:30:00 2026-08-28 EDT
|
5-day change | 1st Jan Change | ||
| 5,800.00 JPY | -0.15% |
|
+0.54% | +19.96% |
| 08-24 | FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome | RE |
| 08-24 | Takeda's Orzeryful Approved in Japan as First Treatment Targeting Narcolepsy Type 1 | MT |
Company Valuation: Takeda Pharmaceutical Company Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,423,454 | 6,762,204 | 6,564,378 | 6,749,675 | 8,948,061 | 9,275,572 | - | - |
| Change | - | 24.68% | -2.93% | 2.82% | 32.57% | 3.66% | - | - |
| Enterprise Value (EV) 1 | 8,919,170 | 10,611,015 | 10,950,330 | 10,725,175 | 5,130,461 | 13,177,788 | 12,976,701 | 12,672,483 |
| Change | - | 18.97% | 3.2% | -2.06% | -52.16% | 156.85% | -1.53% | -2.34% |
| P/E | 23.8x | 21.3x | 45.4x | 64.6x | 46.4x | 46.6x | 29.8x | 24.4x |
| PBR | 0.95x | 1.06x | 0.9x | 1x | 1.2x | 1.24x | 1.25x | 1.24x |
| PEG | - | 0.5x | -0.8x | -2.5x | 0.6x | 22.19x | 0.5x | 1.1x |
| Capitalization / Revenue | 1.52x | 1.68x | 1.54x | 1.47x | 1.99x | 1.98x | 1.95x | 1.9x |
| EV / Revenue | 2.5x | 2.63x | 2.57x | 2.34x | 1.14x | 2.81x | 2.72x | 2.59x |
| EV / EBITDA | 8.54x | 9.19x | 11.6x | 9.71x | 4.54x | 9.92x | 9.15x | 8.54x |
| EV / EBIT | 19.4x | 21.6x | 51.1x | 31.3x | 12.6x | 29.4x | 21.8x | 18.5x |
| EV / FCF | 8.92x | 28.7x | 43.4x | 15.5x | 8.14x | 18.3x | 18.6x | 17.4x |
| FCF Yield | 11.2% | 3.49% | 2.31% | 6.43% | 12.3% | 5.47% | 5.37% | 5.74% |
| Dividend per Share 2 | 180 | 180 | 188 | 196 | 200 | 204.3 | 208.4 | 214.9 |
| Rate of return | 5.15% | 4.14% | 4.49% | 4.44% | 3.53% | 3.52% | 3.59% | 3.7% |
| EPS 2 | 147.1 | 204.3 | 92.09 | 68.36 | 122 | 124.6 | 194.7 | 238.5 |
| Distribution rate | 122% | 88.1% | 204% | 287% | 164% | 164% | 107% | 90.1% |
| Net sales 1 | 3,569,006 | 4,027,478 | 4,263,762 | 4,581,600 | 4,505,700 | 4,686,848 | 4,766,104 | 4,888,874 |
| EBITDA 1 | 1,043,995 | 1,154,905 | 942,077 | 1,103,982 | 1,129,888 | 1,328,526 | 1,418,864 | 1,483,635 |
| EBIT 1 | 460,844 | 490,505 | 214,100 | 342,600 | 408,800 | 448,525 | 595,763 | 686,473 |
| Net income 1 | 230,059 | 317,017 | 144,067 | 107,900 | 191,800 | 193,788 | 317,524 | 376,802 |
| Net Debt 1 | 3,495,716 | 3,848,811 | 4,385,952 | 3,975,500 | -3,817,600 | 3,902,217 | 3,701,130 | 3,396,911 |
| Reference price 2 | 3,498.00 | 4,350.00 | 4,184.00 | 4,413.00 | 5,664.00 | 5,809.00 | 5,809.00 | 5,809.00 |
| Nbr of stocks (in thousands) | 1,550,444 | 1,554,530 | 1,568,924 | 1,529,498 | 1,579,813 | 1,596,759 | - | - |
| Announcement Date | 5/11/22 | 5/11/23 | 5/9/24 | 5/8/25 | 5/13/26 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 46.64x | 2.81x | 9.92x | 3.52% | 58.22B | |
| 33.48x | 12.15x | 24.63x | 0.59% | 1,048B | |
| 29.56x | - | - | 2.02% | 640B | |
| 32.95x | 7.64x | 15.89x | 2.66% | 456B | |
| 20.28x | 4.82x | 11.94x | 2.74% | 362B | |
| 22.04x | 5.68x | 14.08x | 2.82% | 295B | |
| 21.17x | 4.34x | 12.4x | 2.03% | 255B | |
| 27.64x | 7.13x | 12.67x | 2.31% | 236B | |
| 13.24x | 4.76x | 9.94x | 3.83% | 204B | |
| -45.49x | 6.56x | 25.62x | 2.21% | 185B | |
| Average | 20.15x | 6.21x | 15.23x | 2.47% | 373.99B | |
| Weighted average by Cap. | 24.56x | 8.00x | 17.76x | 1.98% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 4502 Stock
- Valuation Takeda Pharmaceutical Company Limited
Select your edition
All financial news and data tailored to specific country editions
